Last reviewed 2026-05-13 · How we verify

Arificial Tear

Massachusetts Eye and Ear Infirmary · FDA-approved active Small molecule

Arificial Tear is a Ophthalmic lubricant Small molecule drug developed by Massachusetts Eye and Ear Infirmary. It is currently FDA-approved for Dry eye syndrome, Ocular surface irritation and discomfort. Also known as: Placebo, Artificial Tear.

Artificial tears are lubricating eye drops that supplement or replace the eye's natural tear film to relieve dryness and irritation.

Artificial tears are lubricating eye drops that supplement or replace the eye's natural tear film to relieve dryness and irritation. Used for Dry eye syndrome, Ocular surface irritation and discomfort.

At a glance

Generic name	Arificial Tear
Also known as	Placebo, Artificial Tear
Sponsor	Massachusetts Eye and Ear Infirmary
Drug class	Ophthalmic lubricant
Modality	Small molecule
Therapeutic area	Ophthalmology
Phase	FDA-approved

Mechanism of action

Artificial tears mimic the composition and function of natural tears, providing lubrication to the ocular surface and protecting the cornea and conjunctiva from desiccation. They help restore the tear film's protective barrier, reduce friction during blinking, and provide comfort by moisturizing dry eye tissues. These formulations typically contain water, electrolytes, and viscosity agents to maintain prolonged contact with the eye surface.

Approved indications

Dry eye syndrome
Ocular surface irritation and discomfort

Common side effects

Transient blurred vision
Eye irritation
Allergic reaction (rare)

Key clinical trials

The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Arificial Tear CI brief — competitive landscape report
Arificial Tear updates RSS · CI watch RSS
Massachusetts Eye and Ear Infirmary portfolio CI

Frequently asked questions about Arificial Tear

What is Arificial Tear?

Arificial Tear is a Ophthalmic lubricant drug developed by Massachusetts Eye and Ear Infirmary, indicated for Dry eye syndrome, Ocular surface irritation and discomfort.

How does Arificial Tear work?

Artificial tears are lubricating eye drops that supplement or replace the eye's natural tear film to relieve dryness and irritation.

What is Arificial Tear used for?

Arificial Tear is indicated for Dry eye syndrome, Ocular surface irritation and discomfort.

Who makes Arificial Tear?

Arificial Tear is developed and marketed by Massachusetts Eye and Ear Infirmary (see full Massachusetts Eye and Ear Infirmary pipeline at /company/massachusetts-eye-and-ear-infirmary).

Is Arificial Tear also known as anything else?

Arificial Tear is also known as Placebo, Artificial Tear.

What drug class is Arificial Tear in?

Arificial Tear belongs to the Ophthalmic lubricant class. See all Ophthalmic lubricant drugs at /class/ophthalmic-lubricant.

What development phase is Arificial Tear in?

Arificial Tear is FDA-approved (marketed).

What are the side effects of Arificial Tear?

Common side effects of Arificial Tear include Transient blurred vision, Eye irritation, Allergic reaction (rare).

Drug class: All Ophthalmic lubricant drugs
Manufacturer: Massachusetts Eye and Ear Infirmary — full pipeline
Therapeutic area: All drugs in Ophthalmology
Indication: Drugs for Dry eye syndrome
Indication: Drugs for Ocular surface irritation and discomfort
Also known as: Placebo, Artificial Tear

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing